Article in American journal of physiology. Endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Dongjoo YouNutritional Sciences and Toxicology Department, University of California Berkeley, Berkeley, California, United States.
Hangjiang RenNutritional Sciences and Toxicology Department, University of California Berkeley, Berkeley, California, United States.ORCID 0000-0002-1687-4963
Byung Chul JungDepartment of Biomedical Laboratory Science, College of Software and Digital Healthcare Convergence, Yonsei University, Wonju, South Korea.ORCID 0000-0003-0732-0122
Natalie Youngji OhNutritional Sciences and Toxicology Department, University of California Berkeley, Berkeley, California, United States.ORCID 0009-0006-3690-4353
Liping WangDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Center, University of Utah, Salt Lake City, Utah, United States.ORCID 0000-0003-3537-0952
John Alan MaschekDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Center, University of Utah, Salt Lake City, Utah, United States.ORCID 0000-0003-3217-2299
Scott A SummersDepartment of Nutrition and Integrative Physiology and the Diabetes and Metabolism Center, University of Utah, Salt Lake City, Utah, United States.
Sona KangNutritional Sciences and Toxicology Department, University of California Berkeley, Berkeley, California, United States.ORCID 0000-0002-9831-677X
Funding
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic DiseasesR44DK116450 · NIDDK · POTRERO HILL THERAPEUTICS, INC. · PI BLITZER, JEREMY, SUMMERS, SCOTT A · 2018 to 2022
$4.7M
Epigenetic regulation of adipose development and remodelingR01DK116008 · NIDDK · UNIVERSITY OF CALIFORNIA BERKELEY · PI Sona Kang · 2018 to 2026
$3.6M
The Role of Ceramides in Skeletal MuscleR01DK115824 · NIDDK · UNIVERSITY OF UTAH · PI SUMMERS, SCOTT A · 2018 to 2021
$2.6M
The Role of Ceramides in the Intestinal Stem CellR01DK131609 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI EDGAR, BRUCE ALEXANDER, SUMMERS, SCOTT A · 2021 to 2025
$2.5M
The Role of Ceramides in the Pancreatic Beta CellR01DK130296 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HOLLAND, WILLIAM L, SUMMERS, SCOTT A · 2022 to 2025
$2.2M
Ceramides in Diastolic Heart FailureR01HL170575 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI WILLIAM L HOLLAND, SCOTT A SUMMERS · 2024 to 2026
$2.1M
HHS | NIH | National Cancer Institute (NCI) U01 CA272259HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK11608HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK116888NHLBI NIH HHS R01 HL170575NIDDK NIH HHS R01 DK115824NIDDK NIH HHS R01 DK116008NIDDK NIH HHS R01 DK130296NIDDK NIH HHS R01 DK131609NIDDK NIH HHS R44 DK116450
6 · The paper itself
Abstract
We previously identified Jumonji domain-containing 8 (JMJD8) as a regulator of lipid droplet (LD) hypertrophy in adipocytes through modulation of AMPK-dependent perilipin-2 (PLIN2) phosphorylation. Given PLIN2's established role in hepatic steatosis, we investigated whether JMJD8 also regulates lipid accumulation in the liver. Here, we report that JMJD8 expression is significantly elevated in the livers of mice fed either a high-fat diet (HFD) or the metabolic-associated fatty liver disease (MAFLD)-inducing Gubra Amylin NASH (GAN) diet. To define the metabolic role of JMJD8 in the liver, we generated liver-specific
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
JMJD8 facilitates hepatic lipid deposition and metabolic dysfunction. · full record | OpenQuestion